newsfilter
← Latest News
GlobeNewswire·

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells Editas Medicine to receive a $70 million payment and may be eligible for...